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Introduction: The aim of this study was to show the emergence of the qnrD gene among fluoroquinolone-
resistantMorganella morganii isolate. The occurrence of mutations in DNA gyrase (gyrA and gyrB) and topoisomerase
IV (parC,parE) genes was also investigated in this strain.
Methodology: 95 clinical Enterobacteria were screened for harbouring the qnrD gene. The clinical isolate of M.
morganii was recovered from urine from a patient hospitalized in the urology unit at Fattouma Bourguiba Hospital,
Tunisia. Antibiotic susceptibility was tested with the agar disk diffusion method. Quinolone susceptibility was
studied with microbroth dilution technique. The investigations of plasmid mediated quinolone resistance (PMQR)
and topoisomerases mutations were performed by polymerase chain reaction and nucleotide sequencing.
Results: This isolate showed high level of resistance to quinolones. The MIC with microbroth dilution technique
was 512 μg/ml for norfloxacin, 256 μg/ml for ofloxacin and ciprofloxacin and 64μg/ml for levofloxacin.
This strain was found to harbour the quinolone resistance determinant qnrD. In addition, this strain harboured two
new gyrB mutations (S463A, S464Y) and one parC mutation (S80I).
Conclusions: This is the first report in Tunisia of qnrD determinant and tow new gyrB muations in M. morganii. The
nosocomial infection due to this proteeae invites further study of its epidemiologic evolution.
Keywords: Morganella morganii, Quinolone resistance, Topoisomerase mutation, qnrDIntroduction
The first qnr gene was observed in the late 1990s and
described as a plasmid-mediated quinolone resistance gene
(PMQR). Since that, five types of qnr genes have been re-
ported: qnrA, qnrB, qnrC, qnrD, and qnrS. Their sequences
are deposited at the following website (http://www.lahey.
org/qnrStudies/). Most were observed in Enterobacteria-
ceae, located on large conjugative multi-resistant plasmids,
such as pMG252 seen in the original qnrA1-positive
strain [1].
The qnrD gene was first described in 2009 on a
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article, unless otherwise stated.Salmonella enterica serovar Kentucky and three Salmonella
enterica serovar Bovismordificans isolates from China [2].
Since this report, qnrD was found in Escherichia coli
[3], M. morganii [4], P. Mirabilis [4,5], Pseudomonas
aeruginosa [5] and Providencia rettgeri [6].
We describe the new gyrB and parC mutations in a
clinical isolate of M. morganii harbouring the rare qnrD
gene that is first reported in Tunisia.Material and methods
Case presentation
On 22 November 2012, a 76-years old male presented to
the urology department with hematuria and burning
micturition that were neglected by the patient since six
months. On presentation, he was not febrile with normal
vital signs and negative urine culture.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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aspect, bifocal with long axis (3 cm). The histopathology
revealed urothelial carcinoma infiltrating high-grade blad-
der (II pTa). On 30/11/2012, underwent a transurethral
resection of bladder tumor. A double-current probe 18 c
was also introduced.
On 19/01/2013 the patient presented an acute pyeloneph-
ritis and the urine culture showed the presence of quinolone
resistant M. morganii. The empiric antibiotic therapy con-
sisted of three doses a day of 2_g Ampicillin during 4 days.
Urine culture subsequently yielded M.morganii. The anti-
biotic regime was then replaced with three doses a day of
cefoxitin 1_g during one week. After this, the urine culture
was negative but the haematuria still existed.
Bacterial strain
M. morganii was isolated from urine and identified using
the Vitek 2 identification system (bioMérieux, Marcy
l’Etoile, France). The antimicrobial susceptibilities of the
M. morganii isolate were determined on Mueller-Hinton
agar by the standard disk diffusion procedure as de-
scribed by the Antibiogram Committee of the French
Society for Microbiology (http://www.sfm.asso.fr). The
microbroth dilution technique was used to determine
the minimal inhibitory concentrations (MIC) for nor-
floxacin, ofloxacin, ciprofloxacin and levofloxacin.
PMQR screening
The qnrA, qnrB, qnrS, qnrC, qnrD, aac-Ib, and qepA
genes were detected by PCR with the primer sets as
described previously [2,7-10].
QnrD primers were used also for the clinical survey of
qnrD gene in other quinolone resistance Enterobacteria-
cae (n = 95) collected from October 2010 to June 2013:
Klebsiella pneumoniae (n = 59), Enterobacter cloaceae
(n = 17), Citrobacter freundii (n = 9), Salmonella spp (n = 6),
Providencia rettgerii (n = 3), M. morganii (n = 1).
Conjugation
The transferability of qnrD gene between the M. morganii
isolate and the E. coli J53Azr recipient were carried out in
LB broth. Cultures of donor and recipient cells in logarith-
mic phase (0.5 ml of each) were added to 4 ml of fresh LB
broth and incubated overnight without shaking. Trans-
conjugants were selected on Trypticase soy agar (TSA)
plates containing sodium azide (100 μg/ml; Sigma Chem-
ical Co., St. Louis, Mo.) for counterselection and gentami-
cin (10 μg/ml) to select for plasmid-encoded resistance.
Detection of mutations in the topoisomerase II and IV
genes
The quinolone resistance-determinant regions (QRDRs)
of gyrA, gyrB, ParC and parE was amplified as described
previously [11]. Products resulting from amplificationswere subjected to sequencing. Analysis and comparison
of nucleotide and amino acid sequence data were carried
out using Lasergene software (version 7.1; DNASTAR,
Wisconsin, USA), and programs available from the
national Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov).
Results
Antibiotic susceptibility of M. morganii
The clinical strain of M. morganii showed a low level of re-
sistance to beta-lactams due to its resistance to ampicillin,
amoxicillin, ticarcillin and piperacillin only. It was suscep-
tible to amoxicillin/clavulanic acid, ticarcillin/clavulanic
acid, piperacillin/tazobactam, cafalotin, cefamandol, cefoxi-
tin, cefotaxim, ceftazidim, cefpirom, aztreonam, imipenem
and ertapenem. This strain was resistant to gentamicin and
tobramycin but susceptible to amikacin. It showed also, de-
creased susceptibility to trimethoprime/sulfamides and
rifampicin. The MIC with microbroth dilution technique
was 512 μg/ml for norfloxacin, 256 μg/ml for ofloxacin
and ciprofloxacin and 64 μg/ml for levofloxacin.
Detection of PMQR genes
The PMQR screening with PCR revealed the presence of
qnrD in M.morganii only. None of the other studied
Enterobacteria harboured the qnrD gene. The sequencing
result showed the presence of qnrD1 in the M. morganii
isolate. qnrA, qnrB, qnrS, qnrC, aac-Ib-cr and qepA genes
were not found in this strain.
Conjugation
The conjugative reaction fails and the qnrD gene couldn’t
be transferred to E.coli J53.
Topoisomerase mutations
Sequencing of PCR products of QRDRs in gyrB and
parC showed two mutations in the QRDR of gyr B at
463 and 464 codons. The first one is an S463A substitu-
tion and the second is an S464Y substitution.
Mutation was found also in the QRDR of parC at
codon 80. It was an S80I substitution.
Discussion
The Gram-negative M. morganii is found in the environ-
ment and as a part of the normal flora of humans. It has
been considered as a rare cause of human infections.
However, it is an important opportunistic pathogen in
urinary tract, soft tissue infections and also in infections
following surgery [12,13]. In this case of study, the old
age of the patient, the bladder tumor and its resection
and the probe introduction after the surgery are risk
factors leading to the urinary tract infection with the
opportunistic M. morganii.
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lones and qnrD was detected. qnrD was not found to be
self transmissible and it could have spread either on a
mobilizable plasmid or on a transferable structure inte-
grated into a conjugative plasmid [6]. The transfer of
quinolone resistance due to qnrD is always studied on
transformants never on transconjugants. In the study of
Hu et al., Proteus mirabilis harbouring qnrD failed to
transfer quinolone resistance to E.coli 600 by conjugation
[14]. The MIC of ciprofloxacin in E.coli DH10B cells in-
creased in the transformants carring the plasmid pBR322
with the cloned qnrD from 0,002 μg/ml to 0,06 μg/ml (by a
factor 32) [2].
However, qnrD positive clinical strains described so far
exhibited a high level of quinolone resistance with cipro-
floxacin MIC ranging from 1 to higher then 32 μg/ml
and they are likely to harbour other quinolone resistance
mechanisms [14,15]. Topoisomerase mutations have not
been always investigated in qnrD positive clinical strains
in order to evaluate how both mechanisms interact. The
gyrA and parE primers used to amlify the QRDRs for
Enterobacteria were not available for M. morganii. The
study of Mazzariol A et al. couldn’t to amplify gyrA and
parC genes in this bacteria and this is due to its un-
known genome [15].
To date, none of M. morganii was described with gyrB
mutations. In this report, we described for the first time,
two new gyrB mutations in M. morganii. In gram-
negative bacilli, gyrB mutations are rare in clinical
strains and they have been described at positions 426,
431, 447, 463, 464 and 466. The Ser 463Ala mutation
has been linked to Klebsiella oxytoca [11].
This is the first report of the previous mutation in qnrD
harbouring M. morganii. The Ser 464 Phe mutation has
been linked to quinolone resistant S.enterica, P.aeruginosa
and P.mirabilis [16-18]. In this study, the gyrB Tyr464
mutation was different from those described previously.
For M. morganii, the first ParC mutation was reported
in the Tunisian study of Mahrouki et al. [19]. It was an
S80I mutation associated to the qnrS 1 gene.
Another ParC mutation (S80R) was also described
previously in this Proteeae [20]. In this study, we
described the first S80I mutation in qnrD-positive M.
morganii. This type of mutation was already observed in
other Enterobacteria but never associated to the qnrD
gene [21].
In summary, we have reported for the first time in
Tunisia the rare qnrD in M. morganii and also found
two new gyrB mutations (S463A and S464Y) and one
parC substitution (S80I). In addition to qnrD gene, both
mutations in gyrB and ParC could contribute to the high
level of resistance to quinolones in this strain. The noso-
comial infection caused by this bacterium invites further
study of its epidemiologic evolution.Competing interests
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